Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522687 | 1.00 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL1980156 | 1.00 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL22713306 | 0.97 | DPP4 (0.65) | DPP4F2ADRA2AADRA2CLMNA | |
| Hydrochloric Acid SCHEMBL3753145 | 0.97 | DPP4 (0.65) | DPP4F2ADRA2AADRA2CLMNA | |
| Bromide SCHEMBL11538603 | 0.97 | DPP4 (0.65) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL3271282 | 0.85 | DPP4 (0.45) | DPP4ADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL20634768 | 0.84 | DPP4 (0.62) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL77070 | 0.83 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL10506371 | 0.83 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL3367415 | 0.83 | DPP4 (0.68) | DPP4F2ADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195459-B | Process for racemization of (5R) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H isoxazol-3-yl ] -2-methyl-benzoic acid | 英特维特国际股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-113242854-B | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid | 英特维特国际股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-3898598-B1 | METHOD FOR PRODUCING (5S)-4-[5-(3,5-DICHLOROPHENYL)-5-(TRIFLUOROMETHYL)-4H-ISOXAZOL-3-YL]-2-METHYL-BENZOIC ACID | INTERVET INT BV (NL) | 2024-09-11 | — | — | EP | disclosed |
| CN-113227060-B | Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid | 英特维特国际股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-11548859-B2 | Method for producing (5,S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzoic acid | INTERVET INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548859-B2 | Method for producing (5,S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzoic acid | INTERVET INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11530187-B2 | Method for producing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid | INTERVET INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530187-B2 | Method for producing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid | INTERVET INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11371067-B2 | Transaminase reactions | CODEXIS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220073479-A1 | Method for Producing (5,S)-4-[5-(3,5-Dichlorophenyl)-5-(Trifluoromethyl)-4Hisoxazol-3-YL]-2-Methyl-Benzoic Acid | INTERVET INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1381590-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-5696134-A | Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof | LG CHEMICAL LIMITED (KR) | 1997-12-09 | — | — | US | disclosed |
| EP-0779296-A2 | D-alpha-aminoalkanoyl-(S)-N-alpha-alkylbenzyl amides useful as intermediates for artificial sweeteners | THE COCA-COLA COMPANY (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0687675-A2 | Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof | LG Chemical Limited (KR) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995017418-A2 | NOVEL INTERMEDIATES FOR THE SYNTHESIS OF L-ASPARTYL-D-α-AMINOALKANOYL-(S)-N-α-ALKYLBENZYL AMIDES USEFUL AS ARTIFICIAL SWEETENERS | THE COCA-COLA COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| US-5286509-A | L-aspartyl-D-α-aminoalkanoyl-(S)-N-alpha-alkylbenzyl amides useful as artificial sweeteners | THE COCA-COLA COMPANY (US) | 1994-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530187-B2 | Method for producing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid | GABRA5, KDM5A, COX5A | DPP4 599/4885F2 1895/4885ADRA2A 1256/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | DPP4 2687/4885F2 1379/4885ADRA2A 1532/4885 |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | DPP4 2617/4885F2 840/4885ADRA2A 1127/4885 |
| US-20220073479-A1 | Method for Producing (5,S)-4-[5-(3,5-Dichlorophenyl)-5-(Trifluoromethyl)-4Hisoxazol-3-YL]-2-Methyl-Benzoic Acid | KDM5A, GABRA5, KDM5B | DPP4 838/4885F2 1283/4885ADRA2A 1161/4885 |
| US-11548859-B2 | Method for producing (5,S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzoic acid | GABRA5, KDM5A, KDM5B | DPP4 728/4885F2 1526/4885ADRA2A 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.